• Wondering whether Xylem stock offers good value at today’s price, or if the recent moves are already pricing in its strengths.
• The share price closed at US$110.28, with a 7 day gain of 2.0%, but it is down 9.2% over the past 30 days and down 19.6% year to date. This may change how you think about both upside potential and risk.
• Over the past 1 year the stock is down 10.0%, while the 3 year return sits at 15.9% and the 5 year return is down 1.2%. This gives useful context for anyone looking at different holding periods. These mixed returns are often when a closer look at valuation methods can be most useful.
• On Simply Wall St’s valuation checks, Xylem scores a full 6 out of 6. The rest of this article will compare what different valuation approaches say about the stock, before finishing with a broader way to think about value beyond the headline numbers.

Approach 1: Xylem Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today using a required rate of return. The idea is to estimate what those future cash flows are worth in today’s dollars.

For Xylem, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow (FCF) is about $960.7m. Analyst and extrapolated estimates in the model indicate FCF of $1,984m by 2030, with a path that includes projected FCF such as $942.8m in 2026 and $1,505.6m in 2028, all in dollar terms.

When all projected cash flows are discounted back, the DCF model used here points to an estimated intrinsic value of about $158.40 per share, compared with the current price of $110.28. Within this framework, that gap is interpreted as the stock trading 30.4% below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Xylem is undervalued by 30.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Xylem Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links the price you pay directly to the earnings the business is currently generating. What counts as a “fair” P/E often reflects how the market views a company’s growth outlook and risk profile, with higher expected growth or lower perceived risk usually justifying a higher multiple.

Xylem currently trades on a P/E of 26.7x. That is close to the wider Machinery industry average of 26.9x and below the peer group average of 32.5x. To go a step further, Simply Wall St calculates a proprietary “Fair Ratio” of 28.5x for Xylem. This is designed to estimate the P/E that might be reasonable given factors such as its earnings growth profile, profit margins, industry, market cap and company specific risks.

This Fair Ratio can be more informative than a simple comparison with peers or the industry, because those broad groups can mix companies with very different growth, risk and profitability characteristics. Setting Xylem’s current P/E of 26.7x against the Fair Ratio of 28.5x points to the stock trading below this tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Xylem Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the numbers you have already seen and let you attach a clear story to them, linking your view of Xylem’s business, its future revenue, earnings and margins to a fair value estimate that you can compare with today’s share price.

On Simply Wall St’s Community page, Narratives are an easy to use tool that connects a company’s story to a financial forecast and then to a fair value. This allows you to see in one place whether your view suggests the stock is trading above or below what you think it is worth and use that to help inform your investment decisions.

Narratives also react when new information such as earnings or news is added. Xylem already has contrasting Narratives on the platform, with a more optimistic view pointing to a fair value of US$186.0 and a more cautious view pointing to US$123.56, showing how two investors looking at the same company can reasonably arrive at very different conclusions.

Do you think there's more to the story for Xylem? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.